Board of Directors
The Board of Directors of Neurosciences Victoria, chaired by Mr Bill Burdett, brings together a balance of scientific, clinical, public policy and commercial expertise.
Mr Burdett graduated in geology at the University of Western Australia and worked in oil exploration for nine years before moving to Melbourne to start a mining research department for the stockbroking firm of A.C. Goode & Co. He became a partner of the firm and in 1984 was appointed Executive Director in charge of Institutional Sales, Research and Corporate Finance.
Following the sale of A.C. Goode & Co. to the National Australia Bank in 1987, Bill became Founding Chairman and Chief Executive of Burdett, Buckeridge & Young, an institutional stockbroker. His previous appointments include; Director of Investment Technology Group, Inc., Director of IRESS Market Technology Ltd, Director of Nossal Institute Limited, Council Member of the Nossal Institute for Global Health and Director of the Victorian Neurotrauma Initiative Limited.
Bill is currently a Director of Australian Friends of Asha Slums.
Mrs Jan West AM
B.Comm, FCA GAICD
Mrs West is a non-Executive Director with experience in public sector, community and private organisations. A Chartered Accountant with 23 years’ previous experience as a Partner at Deloitte, Jan is a Director of Australian Red Cross, Dairy Australia Ltd. and Melbourne Forum Ltd. She is also an independent member of the Audit and Risk Management Committee of the Victorian Department of Health and Human Services and of the Victorian Department of Treasury and Finance.
Her experience offers the Board a depth of knowledge and skills in audit, corporate governance, risk and general business acumen. Jan is a past President of The Institute of Chartered Accountants in Australia (ICAA).
She was appointed a Member of the Order of Australia in 2007 and awarded the Governor General’s Centenary Medal in 2001. Jan is a Fellow of the ICAA and of CPA Australia and a Graduate Member of the Australian Institute of Company Directors.
Dr Andrew Milner
BSc (Hons), MSc, PhD, FASM
Chief Executive Officer and Managing Director
Dr Milner has been the CEO and Managing Director of Neurosciences Victoria since 2006. Andrew obtained his BSc (Hons) and MSc degrees at the University of Melbourne and his PhD at the John Curtin School of Medical Research at the Australian National University.
Andrew is a Member of the Advisory Board of the Melbourne Neuroscience Institute at the University of Melbourne and the Chair of the Australian Research Infrastructure Network Advisory Group.
He is a Fellow of the Australian Society for Microbiology and has worked in animal health and agriculture as Head of Molecular Biology at the Victorian Institute of Animal Science and subsequently as Operations Manager at Daratech Pty Ltd. In the medical arena, he has worked as Pricing Manager for Zeneca and AstraZeneca in Australia, as Director of Development and Commercialisation for Kendle (Australia) and as Managing Director of Mimotopes Pty Ltd.
Ms Debbie Beadle
BSc (Chem)(Hons), FIPTA
Ms Beadle completed a Bachelor of Science with Honours majoring in chemistry from The University of Melbourne before commencing her training as a patent attorney in 1988.
She registered as a patent attorney in 1993 and became a Principal of Griffith Hack in 2003. Debbie has primarily practised as a patent attorney in the fields of chemistry and pharmaceuticals.
From 2009-2011, Debbie had the role of National Practice Group Leader of the Life Sciences & Chemical Group and was elected to the Board of Griffith Hack in November 2011.
Debbie is a Fellow of the Institute of Patent and Trade Mark Attorneys of Australia and a member of Ausbiotech, BioMelbourne Network, Royal Australian Chemical Society, Intellectual Property Society of Australia and New Zealand, Asian Patent Attorneys Association, Association Internationale pour la Protection de la Propriété Intellectuelle and the Australian Institute of Company Directors.
Professor Stephen Davis AM
MD FRCP Edin FRACP
Professor Davis is the inaugural Professor of Translational Neuroscience at the University of Melbourne. He is based at the Royal Melbourne Hospital (RMH) where he is the Director of Neurology and the Director of the Melbourne Brain Centre at the RMH.
He is the immediate past President of the Australian and New Zealand Association of Neurologists (ANZAN) and a past President of the Stroke Society of Australasia. He was the first Co-Chair of the Australasian Stroke Trials network and has extensive experience in stroke trials. He is the President of the World Stroke Organisation, Co-Chair of the World Stroke Academy and is Co-Chair of Neuroscience Trials Australia. He has been a Trustee of the Royal Melbourne Hospital Neuroscience Foundation since its formation in 1992.
He was appointed a Member of the Order of Australia in 2013. He was given the M.J. Eadie Award in 2004 by the Australian and New Zealand Association of Neurologists for career achievements in neuroscience research and the Victorian Health Minister’s Award for outstanding individual achievement in the 2008 Victorian Public Healthcare awards. He is the 2011 recipient of both the American Stroke Association’s William Feinberg Award and the Bethlehem Griffiths Research Foundation Medal.
He is the joint recipient of a National Health and Medical Research Council program grant in stroke. He is a Consulting Editor for Stroke and has co-authored three books, numerous book chapters and over 300 peer-reviewed papers.
His major research interests involve clinical trials in stroke and the use of neuroimaging, particularly multimodal MRI, in the selection of acute stroke treatments. He is the Co-Principal Investigator with Professor Donnan of the EXTEND trial, a stroke trial aimed at extending the time window for thrombolysis using MRI in treatment selection.
Professor Geoffrey Donnan AO
MBBS, MD, FRACP, FRCP (Edin), FAHMS
Professor Donnan is the Director of The Florey Institute of Neuroscience and Mental Health. He is Professor of Neurology at the University of Melbourne and Head of the Florey Department of Neuroscience and Mental Health, University of Melbourne.
His research interest is clinical stroke management and he was co-founder of the Australian Stroke Trials Network and Neuroscience Trials Australia. He is past President of the World Stroke Organisation and received the American Stroke Association William Feinberg Award for excellence in clinical stroke research in 2007. In 2012 he was appointed an Officer of the Order of Australia for his distinguished service to neurology and research contributions. He is the recipient of a number of international awards including the World Stroke Organisation Leadership Award (2012), Karolinska Institute Award (2012) and Wepfer Award of the European Stroke Congress for excellence in stroke research (2014).
Professor Paul Fitzgerald
MBBS, MPM, PhD, FRANZCP
Professor Fitzgerald is Professor of Psychiatry, Deputy Director and Consultant Psychiatrist at the Monash Alfred Psychiatry research centre, a joint research centre of Monash University and the Alfred Hospital in Melbourne. He is also the Director of the TMS program and research unit at The Victoria Clinic, Prahran and a Member of the Scientific Advisory Board of Bionomics.
Paul is a psychiatrist, has a Masters of Psychological Medicine and a research PhD. He runs a substantive research program utilising brain stimulation and neuroimaging techniques including transcranial magnetic stimulation, functional and structural MRI, EEG and near infrared spectroscopy. The program has focused on the conduct of investigative studies of brain function / dysfunction as well as the conduct of a variety of novel clinical trials in mood, psychotic and developmental disorders.
Professor Graeme Jackson
BSc (Hons), MD, FRACP
Professor Jackson is Senior Deputy Director, The Florey Institute of Neuroscience and Mental Health. He is a Professorial Fellow of the Florey Department of Neuroscience and Mental Health, University of Melbourne.
His primary research interest is the application of Magnetic Resonance Imaging techniques to the understanding of epilepsy and brain function. His work is recognised for advancing the diagnosis and treatment of patients with epilepsy. Graeme is a neurologist at the Austin Hospital.
In 2008 he was awarded the National Health and Medical Research Council Excellence Award.
Mr Bruce Kean AM
Dip ChemE, FIEAus, FTS, FAICD, FRSA
Mr Kean was educated in Melbourne, studying chemical engineering and economics. He has served on the boards of many public companies, including as Managing Director of Boral Ltd (1987-1994) and as a Director of AMP (1989-2000).
In community affairs, Bruce is a Director of the APEC Study Centre Advisory Board of the Royal Melbourne Institute of Technology and is a Governor of The Florey Institute of Neuroscience and Mental Health.
He was Chair of the Committee for Economic Development of Australia (1994-2002), The Sir David Martin Foundation (1994-1998) and The Mental Health Research Institute of Victoria (2001-2008) and Chairman of the ATSE Clunies Ross Foundation. He was a Member of the Prime Minister’s Economic and Planning Advisory Committee (1992-1994) and Chair of the Commonwealth Government’s Committee of Inquiry into the Standards and Conformance Infrastructure of Australia (1994-1995). In 1994 he was appointed a Member of the Order of Australia. In 2001 he was awarded the Governor General’s Centenary Medal and in 2013 the inaugural ATSE Medal.
Professor Trevor Kilpatrick
MBBS, PhD, FRACP
Professor Kilpatrick is a Professor of Neurology and Director of the Melbourne Neuroscience Institute at The University of Melbourne. He is the leader of the Multiple Sclerosis (MS) Division at the Florey Institute of Neuroscience and Mental Health and is a neurologist and Head of the MS Unit at the Royal Melbourne Hospital.
Trevor is a clinician scientist whose basic research focuses on the neurobiology of MS, in particular glial cell biology and regenerative medicine.
Trevor has initiated a number of productive clinical research projects and established multicentre collaborations to study the genetics and epidemiology of MS and is developing translational platforms for therapeutics that target neurodegenerative diseases.
Professor Rowe is the Director of Molecular Imaging Research, Department of Molecular Imaging and Therapy, Austin Health and a consultant neurologist to the Memory Disorders Clinic at the Austin Hospital, Melbourne. He has published extensively on SPECT in epilepsy and beta-amyloid imaging in Alzheimer’s disease. He applies state‑of‑the-art neuroimaging technology to develop and confirm new diagnostic tests and biomarkers.
Chris is a Professorial Fellowat The University of Melbourne and the Florey Institute of Neuroscience and Mental Health. He is the Neuroimaging Stream Leader of the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) and of the CRC for Mental Health and the former Chair, Neuroimaging Professional Interest Area, US Alzheimer’s Association.
In 2011 he received the Kuhl-Lassen Award, US Society of Nuclear Medicine, for his work in developing a test for the treatment of epilepsy and the diagnosis of Alzheimer’s disease. He is the first Australian researcher to receive a major international award from this Society.
Professor Rob Shepherd
BSc, DipEd, PhD
Professor Rob Shepherd is the Director of The Bionics Institute and the Head of the Medical Bionics Department at The University of Melbourne.
Rob has an international reputation as an expert in the field of neural prostheses. He led the preclinical teams that have demonstrated the safety and efficacy of Cochlear's bionic ear in both adults and children and more recently his team developed a prototype bionic eye as part of an Australia-wide collaboration – Bionic Vision Australia – to develop a commercial bionic eye.
In his administrative role, Rob has overseen the expansion of the Bionic Ear Institute into the Bionics Institute and has widened the research portfolio to include cochlear implants, retinal prostheses and the development of a neurobionic platform technology designed to alleviate a range of intractable and debilitating central nervous system disorders (e.g., epilepsy, Parkinson’s disease and pain management) via central nervous system based neural prostheses.
Professor Ian Smith
Professor Smith is Vice-Provost (Research & Research Infrastructure) at Monash University. Ian completed his first degree in Newcastle upon Tyne England and moved to Australia in 1984 to complete his PhD at Prince Henry’s Institute Melbourne. In 1991 Ian moved to the Baker Heart Research Institute and was Associate Director until his move to Monash University in 2004. As Vice-Provost (Research & Research Infrastructure) Ian has responsibility for the oversight and management of the University’s technology transfer activities, research alliances and research infrastructure as well as developing and implementing strategies to meet future university technology transfer, research, and research infrastructure needs.
Ian is also a Professorial Fellow in the Department of Biochemistry and Molecular Biology at Monash University where he runs his research group. He is an accomplished medical researcher and is recognised as a leader in his field. His research applies proteomics technologies to study the proteases involved in the generation and metabolism of peptide regulators involved in both brain and cardiovascular function. This research has resulted in over 240 publications and many patents. He receives regular invitations to speak at international meetings, many as a plenary speaker. His research has had a direct impact on human health and has led to changes in clinical practice.
Ian was a co-founder of a proteomics-based, publicly listed, biotechnology company and he continues to collaborate and consult widely with the pharmaceutical and biotechnology industry. Ian serves on six international editorial boards and over the years has held office-bearing positions in a number of national and international societies and had an active involvement in the organisation of numerous national and international scientific meetings.
He has held and continues to hold, a variety of senior government and non-government advisory board / committee memberships and currently holds the following positions: Adjunct Professor, Warwick University UK; Council and Board Member, Australian Institute of Nuclear Science and Engineering (AINSE); Non Executive Director, Auspep Pty Ltd; Non Executive Director, Victorian Endowment for Science, Knowledge and Innovation (VESKI); Director, Victorian node Proteomics Australia, Bioplatforms Australia (BPA); Chairman, BioImaging International External Advisory Board; Chairman, ESFRI Roadmap for Research Infrastructures and Chairman, Euro‑Bioimaging.
Ms Marion Thompson
Marion has an extensive background in providing executive support at the senior level. Prior to joining NSV in 2002 she spent some 20 years in the Victorian public sector in positions at Museum Victoria and the former Land Conservation Council.